Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 1/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.53 |
| ▸ | CAMK1D | Q8IU85 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.38 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20451368 | 1.00 | RET (0.53) | RETMAPK14CAMK1DHDAC6ALOX15 | |
| SCHEMBL3653711 | 1.00 | RET (0.53) | RETMAPK14CAMK1DHDAC6ALOX15 | |
| SCHEMBL14452951 | 1.00 | RET (0.53) | RETMAPK14CAMK1DHDAC6ALOX15 | |
| SCHEMBL31089443 | 1.00 | RET (0.53) | RETMAPK14CAMK1DHDAC6ALOX15 | |
| SCHEMBL31509006 | 1.00 | RET (0.53) | RETMAPK14CAMK1DHDAC6ALOX15 | |
| SCHEMBL3653708 | 1.00 | RET (0.53) | RETMAPK14CAMK1DHDAC6ALOX15 | |
| SCHEMBL8991540 | 1.00 | RET (0.53) | RETMAPK14CAMK1DHDAC6ALOX15 | |
| SCHEMBL596246 | 1.00 | RET (0.53) | RETMAPK14CAMK1DHDAC6ALOX15 | |
| SCHEMBL3651148 | 1.00 | RET (0.53) | RETMAPK14CAMK1DHDAC6ALOX15 | |
| SCHEMBL8991537 | 1.00 | RET (0.53) | RETMAPK14CAMK1DHDAC6ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2207766-A1 | NOVEL SULFAMATE COMPOUNDS FOR MEDICAL USE | Abbott Products GmbH (DE) | 2010-07-21 | — | — | EP | claimed |
| US-20090104126-A1 | Sulfamate Compounds and Uses Thereof | SOLVAY PHARMACEUTICALS GMBH (DE) | 2009-04-23 | — | — | US | claimed |
| WO-2009050252-A1 | NOVEL SULFAMATE COMPOUNDS FOR MEDICAL USE | SOLVAY PHARMACEUTICALS GMBH (DE) | 2009-04-23 | — | — | WO | claimed |
| US-20210346369-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2021-11-11 | — | — | US | disclosed |
| US-20200345717-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2020-11-05 | — | — | US | disclosed |
| EP-2768830-B1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2018-08-29 | — | — | EP | disclosed |
| US-20180221363-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2018-08-09 | — | — | US | disclosed |
| US-9877958-B2 | Apoptosis-induced agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2018-01-30 | — | — | US | disclosed |
| EP-3266776-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Inc. (US) | 2018-01-10 | — | — | EP | disclosed |
| US-20160206611-A1 | APOPTOSIS-INDUCED AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2016-07-21 | — | — | US | disclosed |
| US-9266877-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-20150152097-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2015-06-04 | — | — | US | disclosed |
| US-8940737-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-20130096121-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2013-04-18 | — | — | US | disclosed |
| EP-2207766-A1 | NOVEL SULFAMATE COMPOUNDS FOR MEDICAL USE | Abbott Products GmbH (DE) | 2010-07-21 | — | — | EP | disclosed |
| WO-2009050252-A1 | NOVEL SULFAMATE COMPOUNDS FOR MEDICAL USE | SOLVAY PHARMACEUTICALS GMBH (DE) | 2009-04-23 | — | — | WO | disclosed |
| US-20090104126-A1 | Sulfamate Compounds and Uses Thereof | SOLVAY PHARMACEUTICALS GMBH (DE) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200345717-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BAX, BCL2, BCL3 | RET 3964/4885MAPK14 1372/4885CAMK1D 593/4885 |
| US-20210346369-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BAX, BCL2, BCL3 | RET 3964/4885MAPK14 1372/4885CAMK1D 593/4885 |
| US-20180221363-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BAX, BCL2, BCL3 | RET 3964/4885MAPK14 1372/4885CAMK1D 593/4885 |
| US-20130096121-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2A1, BCL2L1, BCL2L11 | RET 4600/4885MAPK14 2034/4885CAMK1D 2032/4885 |
| US-20160206611-A1 | APOPTOSIS-INDUCED AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BAX, BCL2, BCL3 | RET 3982/4885MAPK14 1357/4885CAMK1D 640/4885 |
| US-20090104126-A1 | Sulfamate Compounds and Uses Thereof | SULT1A1, SULT1E1, SULT2A1 | RET 555/4885MAPK14 3761/4885CAMK1D 4417/4885 |
| US-20150152097-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BAX, BCL2, BCL3 | RET 3964/4885MAPK14 1372/4885CAMK1D 593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.